Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer

Medical Oncology

Volumn 31, Issue 11, 2014, Pages 1-6

  Yu, Hong ^a   Li, Hui ^b   Qian, Hua ^a   Jiao, Xia ^a   Zhu, Xiaowei ^a   Jiang, Xiaoqin ^a   Dai, Guihong ^a   Huang, Junxing ^a  

^a TAIZHOU PEOPLE S HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Metastasis; MicroRNA; miR 301a; Prognosis; Triple negative breast cancer

Indexed keywords

MICRORNA; MICRORNA 301A; UNCLASSIFIED DRUG; MIRN301 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PARTIAL MASTECTOMY; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SURVIVAL RATE; TISSUE SECTION; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; BIOSYNTHESIS; METABOLISM; MORTALITY; PHYSIOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TRENDS; TRIPLE NEGATIVE BREAST NEOPLASMS; UPREGULATION;

ADULT; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84919914035     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0283-2     Document Type: Article

References (24)

1. Burney IA, Furrukh M, Al-Moundhri MS. What are our options in the fight against breast cancer? Sultan Qaboos Univ Med J. 2014;14(2):e149–51.
2. Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–89. doi:10.1016/S1470-2045(13)70567-9.
3. Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK. Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013;19(23):6389–97. doi:10.1158/1078-0432.CCR-13-0838.
4. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, Group EGW. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii11–9. doi:10.1093/annonc/mds232.
5. Cordes KR, Srivastava D. MicroRNA regulation of cardiovascular development. Circ Res. 2009;104(6):724–32. doi:10.1161/CIRCRESAHA.108.192872.
6. Li L, Qiu XG, Lv PW, Wang F. miR-639 promotes the proliferation and invasion of breast cancer cell in vitro. Cancer Cell Int. 2014;14:39. doi:10.1186/1475-2867-14-39.
7. Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis. 2012;33(6):1126–33. doi:10.1093/carcin/bgs140.
8. Chen Q, Si Q, Xiao S, Xie Q, Lin J, Wang C, et al. Prognostic significance of serum miR-17-5p in lung cancer. Med Oncol. 2013;30(1):353. doi:10.1007/s12032-012-0353-2.
9. Munker R, Calin GA. MicroRNA profiling in cancer. Clin Sci (Lond). 2011;121(4):141–58. doi:10.1042/CS20110005.
10. Wu C, Cao Y, He Z, He J, Hu C, Duan H, et al. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med. 2014;232(2):85–95.
11. Zhu J, Zheng Z, Wang J, Sun J, Wang P, Cheng X, et al. Different miRNA expression profiles between human breast cancer tumors and serum. Front Genet. 2014;5:149. doi:10.3389/fgene.2014.00149.
12. Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 2011;71(8):2926–37. doi:10.1158/0008-5472.CAN-10-3369.
13. Wang M, Li C, Yu B, Su L, Li J, Ju J, et al. Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer. J Gastroenterol. 2013;48(9):1023–33. doi:10.1007/s00535-012-0733-6.
14. Ma F, Zhang J, Zhong L, Wang L, Liu Y, Wang Y, et al. Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/beta-catenin signaling. Gene. 2014;535(2):191–7. doi:10.1016/j.gene.2013.11.035.
15. Shah NR, Chen H. MicroRNAs in pathogenesis of breast cancer: implications in diagnosis and treatment. World J Clin Oncol. 2014;5(2):48–60. doi:10.5306/wjco.v5.i2.48.
16. Su H, Jin X, Zhang X, Xue S, Deng X, Shen L, et al. Identification of microRNAs involved in the radioresistance of esophageal cancer cells. Cell Biol Int. 2014;38(3):318–25. doi:10.1002/cbin.10202.
17. Gan R, Yang Y, Yang X, Zhao L, Lu J, Meng QH. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP. Cancer Gene Ther. 2014;21(7):290–6. doi:10.1038/cgt.2014.29.
18. Yu H, Duan B, Jiang L, Lin M, Sheng H, Huang J, et al. Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy. Am J Transl Res. 2013;6(1):71–7.
19. Xu XD, He XJ, Tao HQ, Zhang W, Wang YY, Ye ZY, et al. Abnormal expression of miR-301a in gastric cancer associated with progression and poor prognosis. J Surg Oncol. 2013;108(3):197–202. doi:10.1002/jso.23374.
20. Zhou P, Jiang W, Wu L, Chang R, Wu K, Wang Z. miR-301a is a candidate oncogene that targets the homeobox gene Gax in human hepatocellular carcinoma. Dig Dis Sci. 2012;57(5):1171–80. doi:10.1007/s10620-012-2099-2.
21. Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ, et al. miR-301a as an NF-kappaB activator in pancreatic cancer cells. EMBO J. 2011;30(1):57–67. doi:10.1038/emboj.2010.296.
22. Chen Z, Chen LY, Dai HY, Wang P, Gao S, Wang K. miR-301a promotes pancreatic cancer cell proliferation by directly inhibiting Bim expression. J Cell Biochem. 2012;113(10):3229–35. doi:10.1002/jcb.24200.
23. Cao G, Huang B, Liu Z, Zhang J, Xu H, Xia W, et al. Intronic miR-301 feedback regulates its host gene, ska2, in A549 cells by targeting MEOX2 to affect ERK/CREB pathways. Biochem Biophys Res Commun. 2010;396(4):978–82. doi:10.1016/j.bbrc.2010.05.037.
24. Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE et al. Beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell. 2011;20(6):741–54. doi:10.1016/j.ccr.2011.10.030.